(PO136) Prevalence of Endodontic Treatment on Patients at Risk of Medication-Related Osteonecrosis of the Jaw

Abstract: The aims of this study are to determine the prevalence of how often endodontists are involved in treating patients at risk of developing medication-related osteonecrosis of the jaw (MRONJ), and to determine how likely endodontists are to treat teeth with “questionable” or “unfavorable” prognosis in such a patient cohort. A survey questionnaire through REDCap software was created and uploaded onto the American Association of Endodontists (AAE) website. Preliminary results reveal: Most endodontists treat 1-4 patients taking RANK-L medication for osteoporosis/osteopenia (53.13%) monthly. Most endodontists never treat patients taking romosozumab medication for osteoporosis/osteopenia monthly. 93% of endodontists are likely to treat teeth with “questionable” prognosis if the patient is taking an antiresorptive medication due to a history of osteonecrosis of the jaw (ONJ), or if the patient is taking the antiresorptive medication for cancer treatment, osteopenia/osteoporosis, or for other medical reasons. Endodontists are likely to treat teeth with “unfavorable” prognosis if the patient is taking an antiresorptive medication due to ONJ (75.76%), or if the patient is taking antiresorptive medication for cancer treatment (72.73%), for osteopenia/osteoporosis (45.45%), or for other medical reasons (51.52%). Most endodontists treat 1-4 patients taking bisphosphonate medication for cancer treatment (51.52%), for osteoporosis/osteopenia (35.35%), or for other medical reasons (36.36%) monthly. Most endodontists treat 1-4 patients taking bisphosphonate and RANK-L medications monthly and never treat patients taking romosozumab. Endodontists are likely to treat teeth with “questionable” and “unfavorable” prognosis if the patient is taking an antiresorptive medication.